CEO Lawrence Blatt (Aligos)
December 7, 2020 11:16 AM EST
Deals

With a po­ten­tial $458M per tar­get pay­day, Ali­gos teams up with Mer­ck hop­ing to re­verse biotech's re­cent NASH mal­adies

Max Gelman

Senior Editor

Just a few months af­ter go­ing pub­lic with a $150 mil­lion IPO, Ali­gos Ther­a­peu­tics $AL­GS is aim­ing to fur­ther cap­i­tal­ize on its mo­men­tum with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times